giant polypoid basal cell carcinoma of the lower extremity

Less than 1% of basal cell carcinomas are giant basal cell carcinomas. Giant basal cell carcinomas are rare. They preferentially involve the trunk and are commonly associated with neglect. Giant basal cell carcinomas of 10 cm or greater are associated with a high rate of metastasis. We report a case of giant basal cell carcinoma of the leg which is not associated with neglect and no signs of metastasis, despite being more than 10 cm in diameter. The present paper includes a brief review of the literature

persian version of the cardiff acne disability index. reliability and validity study

The Cardiff Acne Disability Index [CADI] assesses the impact of acne on a patients life. The aim of the present study was to translate the CADI into Persian language and to validate the Persian version. Using standard forward-backward translation, 2 bilinguals translated the CADI into Persian language. We back translated it into English and the final version was provided. We conducted this study from February through December 2004 on 100 patients with acne attending the Department of Dermatology, Jahrom Medical School, Jahrom, Iran who completed the Persian version of the CADI questionnaire. We carried out all statistical analyses using the Statistical Package for the Social Sciences version 11 for Windows. A total of 100 patients [15 men, 85 women] with acne participated in this study. The mean age of the patients was 20.76 +/- 2.94 years. Scores of the CADI ranged from 2-14 [7.57 +/- 2.58]. Reliability analysis showed a satisfactory result [Cronbachs alpha coefficient = 0.79]. Moreover, Pearsons correlation coefficient of 0.72 demonstrated the good internal consistency of the scale. The Persian version of the CADI questionnaire is a reliable, valid, and valuable tool for assessing the impact of acne on a patient's life

Cleft lip and palate in southwestern Iran: an epidemiologic study of live births

Cleft lip with or without cleft palate [CL/P], is the most common congenital anomaly in the head and neck worldwide. We studied the prevalence of cleft lip [CL] and palate [CP] in Shiraz, which is located in southwestern Iran. Data was collected from the teaching hospitals of the Shiraz University of Medical Sciences. Records of 147 608 consecutive live births delivered in three hospitals during the 10 years from November 1993 to November 2003 were reviewed. One hundred nineteen cases of CL/P or CP alone were registered for a prevalence of 0.80 per thousand live births. The overall male/female ratio was 1.25. The male/female ratio was 1.22 in the CL patients and 1.58 in the CL/P patients. A male predominance was obvious in both groups. This study shows that the prevalence rate of CL and CP in southwestern Iran is closer to the low prevalence reported in African countries and is lower than the prevalence reported in previous reports in Caucasians

Efficacy of topical immunotherapy of extensive and/or chronic alopecia areata with diphencyprone

Highly variable results of topical immunotherapy with diphencyprone [DPC] in the treatment of alopecia areata have been reported so far. The purpose of this study was to evaluate the efficacy and tolerability of DPC in the treatment of severe and chronic alopecia areata. Twenty-eight patients [16 female and 12 male, 10-35 years old, mean age 25 years] with chronic and/or extensive alopecia areata were enrolled in an open-label clinical trial. After sensitization with 2% DPC, progressively higher concentrations beginning at 0.001% were applied weekly for 6 months to one side of the scalp. The maximum concentration of DPC was 2%.Twenty-seven of 28 patients completed therapy. The overall response rate was 81.5% [22 cases]. Complete response [90% -100% terminal hair re-growth] was obtained in 22.2% [6 cases] and partial response [10%-90% terminal hair re-growth] in 59.3% [16 cases], and 18.5% [5 cases] showed no regrowth. In all patients an eczematous reaction consisting of erythema, itching, and scaling at the site of application was observed. Other observed side effects included occipital lymphadenopathy in 40.7% [11 cases], severe eczema /blister formation in 40.7% [11 cases], hyperpigmentation in 18.5% [5 cases]. Notably, partial recurrence was observed in 66.7% [18 cases] of these patients after 6 to 12 months of follow up. Topical DPC treatment for alopecia areata is an effective therapy with a relatively high relapse rate